CLINICAL TRIALS PROFILE FOR ARIPIPRAZOLE LAUROXIL
✉ Email this page to a colleague
All Clinical Trials for aripiprazole lauroxil
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT01469039 ↗ | A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia | Completed | Alkermes, Inc. | Phase 3 | 2011-12-01 | The study will determine the efficacy of ALKS 9072 (also known as aripiprazole lauroxil or ALKS 9070) for the treatment of schizophrenia in subjects experiencing an acute exacerbation. |
NCT02320032 ↗ | An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia | Completed | Alkermes, Inc. | Phase 1 | 2014-12-01 | This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of various doses and dosing intervals of aripiprazole lauroxil. |
NCT02634320 ↗ | A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia | Completed | Alkermes, Inc. | Phase 4 | 2015-12-01 | This study will evaluate the safety and tolerability of aripiprazole lauroxil (also known as ARISTADA, ALKS 9070). |
NCT02636842 ↗ | A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder | Completed | Alkermes, Inc. | Phase 1 | 2015-12-01 | The study will determine the safety, tolerability, and pharmacokinetics of aripiprazole lauroxil in adults with schizophrenia or schizoaffective disorder. |
NCT03345979 ↗ | A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia | Completed | Alkermes, Inc. | Phase 3 | 2017-11-15 | This study will evaluate the efficacy of initiating treatment of schizophrenia with ARISTADA INITIO plus 30 mg oral aripiprazole followed by a 2-month dose of AL. |
NCT04203056 ↗ | Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode | Recruiting | Alkermes, Inc. | Phase 4 | 2019-12-16 | This 12-month study will evaluate the efficacy of aripiprazole lauroxil compared to oral aripiprazole in preventing the re-emergence of psychotic symptoms in patients with a recent onset of schizophrenia. |
NCT04203056 ↗ | Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode | Recruiting | University of California, Los Angeles | Phase 4 | 2019-12-16 | This 12-month study will evaluate the efficacy of aripiprazole lauroxil compared to oral aripiprazole in preventing the re-emergence of psychotic symptoms in patients with a recent onset of schizophrenia. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for aripiprazole lauroxil
Condition Name
Clinical Trial Locations for aripiprazole lauroxil
Trials by Country
Clinical Trial Progress for aripiprazole lauroxil
Clinical Trial Phase
Clinical Trial Sponsors for aripiprazole lauroxil
Sponsor Name